ReviewEndocrine2025
Fructose and insulin: A sweet sabotage hypothesis?
Review in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development landscape of ketohexokinase-C (KHK-C) inhibitors for fructose-driven metabolic disorders: from hit discovery to clinical trials.RSC medicinal chemistry · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blood glucose level is hormonally regulated by insulin and glucagon, secreted by pancreatic β-cells and α-cells, respectively. In this article, we present our hypothesis that how glucose and fructose metabolism regulate insulin secretion, and that fructose 1-phosphate–induced futile cycle affects β-cell function and contributes to metabolic diseases. We hypothesize that glucose and fructose differentially regulate insulin secretion through distinct metabolic pathways. Glucose uptake via GLUT1 and its subsequent metabolism increase the ATP/ADP ratio, leading to KATP channel closure, membrane depolarization, Ca²⁺ influx, and insulin vesicle exocytosis. Concurrent tau phosphorylation promotes microtubule disassembly, facilitating insulin release. In contrast, fructose uptake through GLUT2, its phosphorylation by fructokinase to fructose 1-phosphate (F1P), and subsequent activation of glucokinase (GK) and fructose 1,6-bisphosphatase-1 (FBPase-1) induce a futile cycle characterized by continuous interconversion between fructose 6-phosphate and fructose 1,6-bisphosphate. This cycle lowers the ATP/ADP ratio, impairs tau phosphorylation and glucose-stimulated insulin secretion, and diverts intermediates toward lipogenesis. Thus, while glucose maintains insulin secretion via regulated glycolysis and energy production, fructose metabolism disrupts this balance through F1P-driven futile cycle, reducing ATP availability, impairing insulin release, and promoting lipid synthesis. Understanding this mechanism provides insight into the adverse effects of dietary fructose on β-cell function.
Indexed as
Identifiers
41091296What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.